Thomas Walther, PhD

CEO of Constant Therapeutics LLC | General Manager of Xitra Therapeutics GmbH | Head of Research Group, Medical School Berlin (MSB)

Dr. Walther is an esteemed leader in pharmacology and drug development. He is the CEO of Constant Therapeutics LLC, General Manager of Xitra Therapeutics GmbH. He is also head of a research group at the Medical School Berlin (MSB). His work focuses on cardiovascular and metabolic (patho)physiology, molecular pharmacology, and the development and implementation of new treatments for chronic diseases.

Dr. Walther’s research led to the discovery of the Mas and MrgD receptors related to angiotensin (1-7) signaling, which are pivotal in cardiovascular health. With over 210 publications and 180 invited presentations, he has significantly advanced understanding of peptide systems in chronic diseases.

He has held leadership roles at renowned institutions, including the University of Cork, University of Giessen, and University of Hull. Before focusing on business development, his academic research has been supported by competitive funding, including over €9.35 million in research grants, and has led to 24 patent applications.

Notable Positions

  • CEO, Constant Therapeutics LLC (2024 - Present)

  • General Manager, Xitra Therapeutics GmbH (2021 - Present)

  • Head of Research Group, Institute of Medical Biochemistry, Medical School Berlin (MSB) (2024 - Present)

  • Chair in Pharmacology and Head of Department of Pharmacology and Therapeutics, University College Cork (UCC) (2013 - 2020)

Education

  • Master in Biology, Martin-Luther-University Halle Wittenberg

  • PhD in Chemistry, Max Delbrück Center Berlin-Buch/Free University Berlin

  • Habilitation in Molecular Cardiology, Free University Berlin

Key Contributions

  • Publications in journals like Science, Nature, and The Lancet

  • Focused on the role of angiotensin (1-7) in cardiovascular diseases and tumor therapy

  • Supervised 17 PhD students and secured major funding for novel drug development

Professor Walther continues to lead groundbreaking research in pharmacology, with a focus on improving treatment strategies for chronic diseases.